Arcadia Biosciences, Inc.
RKDA
$3.60
$0.020.56%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 12.29% | 23.81% | 20.65% | 9.60% | 0.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.29% | 23.81% | 20.65% | 9.60% | 0.79% |
| Cost of Revenue | 40.57% | 65.37% | 53.11% | 11.32% | -22.93% |
| Gross Profit | -13.59% | -10.49% | -7.11% | 7.41% | 40.29% |
| SG&A Expenses | -6.90% | 5.40% | 21.03% | -0.70% | -25.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.68% | 16.90% | 27.64% | 1.81% | -24.93% |
| Operating Income | 4.37% | -11.80% | -33.35% | 2.87% | 36.77% |
| Income Before Tax | -595.03% | -3,806.08% | -167.73% | 39.59% | 92.65% |
| Income Tax Expenses | 14.29% | 14.29% | 0.00% | 0.00% | -50.00% |
| Earnings from Continuing Operations | -589.47% | -3,664.89% | -168.93% | 39.54% | 92.59% |
| Earnings from Discontinued Operations | 99.47% | 93.07% | 84.70% | 60.25% | 8.90% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -100.00% |
| Net Income | 13.04% | -11.10% | 71.28% | 49.66% | 62.09% |
| EBIT | 4.37% | -11.80% | -33.35% | 2.87% | 36.77% |
| EBITDA | 2.83% | -15.42% | -38.89% | 0.62% | 36.30% |
| EPS Basic | 13.28% | -10.71% | 71.33% | 63.75% | 76.80% |
| Normalized Basic EPS | -71.59% | -147.65% | -544.28% | 33.50% | 70.74% |
| EPS Diluted | 21.40% | -1.66% | 62.63% | 60.57% | 74.35% |
| Normalized Diluted EPS | -56.91% | -164.92% | -458.40% | 43.57% | 78.84% |
| Average Basic Shares Outstanding | 0.28% | 0.30% | 0.30% | 10.30% | 28.05% |
| Average Diluted Shares Outstanding | -7.74% | -7.79% | 33.67% | 47.02% | 70.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |